SGC launches third phase with $49.9 million in funding

Guest Contributor
October 17, 2011

The Toronto-based Structural Genomics Consortium (SGC) has received $48.9 million to launch its third four-year phase. The funding is 30% less than in previous phases due primarily to the closure of the SGC laboratory at Karolinska Institutet in suburban Stockholm last June. The funding — 45% of which comes from commercial entities — will support SGC's two remaining labs at the Univ of Toronto and the Univ of Oxford. Since its formation in 2004, SGC has placed more than 1,300 three-dimensional protein structures in the public domain. Organizations providing follow-on funding are the Canadian Institutes of Health Research, GlaxoSmithKline, Novartis Research Foundation, Ontario Ministry of Research and Innovation and the Wellcome Trust. New contributing members are Eli Lilly Canada and Pfizer Inc. Genome Canada was an early supporter of SGC, pioneering a new model for pre-competitive drug discovery based on open access. A breakdown of funding from the specific organizations was not divulged ….

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.